MX2012009129A - Composiciones y metodos para tratar la obesidad y condiciones relacionadas con la obesidad. - Google Patents

Composiciones y metodos para tratar la obesidad y condiciones relacionadas con la obesidad.

Info

Publication number
MX2012009129A
MX2012009129A MX2012009129A MX2012009129A MX2012009129A MX 2012009129 A MX2012009129 A MX 2012009129A MX 2012009129 A MX2012009129 A MX 2012009129A MX 2012009129 A MX2012009129 A MX 2012009129A MX 2012009129 A MX2012009129 A MX 2012009129A
Authority
MX
Mexico
Prior art keywords
orlistat
obesity
ingesting
compositions
methods
Prior art date
Application number
MX2012009129A
Other languages
English (en)
Inventor
Ronald Thompson
Original Assignee
Chelatexx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chelatexx Llc filed Critical Chelatexx Llc
Publication of MX2012009129A publication Critical patent/MX2012009129A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Un método para tratar de manera efectiva los acontecimientos adversos de la ingesta de un inhibidor de la lipasa como orlistat y mantener la eficacia del orlistat ingerido, método que comprende las etapas de: ingerir un compuesto de orlistat para unir de manera irreversible las enzimas lipasas del tracto gastrointestinal; ingerir un compuesto de simeticona para que las grasas no digeridas se mantengan en un estado emulsionado en el intestino; e ingerir carbón activado con recubrimiento entérico para absorber las grasas emulsionadas solamente en el intestino inferior, evitándose los efectos adversos asociados con la ingesta de orlistat solo.
MX2012009129A 2010-02-08 2010-07-22 Composiciones y metodos para tratar la obesidad y condiciones relacionadas con la obesidad. MX2012009129A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/658,331 US8110186B2 (en) 2006-09-18 2010-02-08 Method to maintain the efficacy of orlistat
PCT/US2010/042835 WO2011096950A1 (en) 2010-02-08 2010-07-22 Compositions and methods for treating obesity and obesity-related conditions

Publications (1)

Publication Number Publication Date
MX2012009129A true MX2012009129A (es) 2012-12-05

Family

ID=44355704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009129A MX2012009129A (es) 2010-02-08 2010-07-22 Composiciones y metodos para tratar la obesidad y condiciones relacionadas con la obesidad.

Country Status (8)

Country Link
US (1) US8110186B2 (es)
EP (1) EP2533635A4 (es)
KR (1) KR20120120960A (es)
AU (1) AU2010345069A1 (es)
BR (1) BR112012019728A2 (es)
CA (1) CA2789144A1 (es)
MX (1) MX2012009129A (es)
WO (1) WO2011096950A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797243A (zh) * 2012-09-21 2015-07-22 辉凌公司 药物组合物
BR112017002777A2 (pt) 2014-08-11 2018-01-02 Perora Gmbh formulação compreendendo partículas
ES2791228T3 (es) 2014-08-11 2020-11-03 Perora Gmbh Método para la inducción de saciedad
HUE057093T2 (hu) 2014-12-17 2022-04-28 Empros Pharma Ab Orlisztát és akarbóz módosított hatóanyagleadású készítménye elhízás és ezzel kapcsolatos metabolikus rendellenességek kezelésére
CA2989520A1 (en) 2015-07-07 2017-01-12 Perora Gmbh Composition comprising satiety-inducing particles
EP3319592A1 (en) 2015-07-07 2018-05-16 perora GmbH Method of inducing satiety

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229132A (en) * 1985-02-22 1993-07-20 Grimberg Georges Serge Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
JPH03120227A (ja) * 1989-10-02 1991-05-22 Shigeo Ochi 飲食物消化分解産物吸収抑制剤
US5827497A (en) * 1996-08-14 1998-10-27 Mayo Foundation For Medical Education And Research Charcoal-radionuclide agents for measurement of gastrointestinal transit
JPH1129485A (ja) * 1997-07-10 1999-02-02 Kureha Chem Ind Co Ltd 抗肥満剤
JP2005247784A (ja) * 2004-03-05 2005-09-15 Ueda Shikimono Kojo:Kk 排便消臭剤
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
US20100015184A1 (en) * 2006-12-13 2010-01-21 Tuel Stephen M Methods of Making Pharmaceutical Components for Customized Drug Products

Also Published As

Publication number Publication date
US20100183686A1 (en) 2010-07-22
KR20120120960A (ko) 2012-11-02
AU2010345069A1 (en) 2012-09-20
BR112012019728A2 (pt) 2019-09-24
CA2789144A1 (en) 2011-08-11
US8110186B2 (en) 2012-02-07
EP2533635A1 (en) 2012-12-19
WO2011096950A1 (en) 2011-08-11
EP2533635A4 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
MX2012009129A (es) Composiciones y metodos para tratar la obesidad y condiciones relacionadas con la obesidad.
EP3354640A3 (en) Mif inhibitors and their uses
WO2010074588A8 (en) Pharmaceutical compounds
WO2011010921A3 (en) Compositions for reducing gastro-intestinal methanogenesis in ruminants
WO2009089494A3 (en) Pharmaceutical compositions
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2010088001A3 (en) Sequestration of compounds from microorganisms
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX343362B (es) Composicion de aceite y metodo para producir la misma.
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2011066282A3 (en) Methods and compositions for treating oxalate-related conditions
WO2010120431A3 (en) Methods for the prevention and treatment of burn injuries and secondary complications
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
WO2011160062A3 (en) Compositions and methods for treating inflammatory conditions
IL197362A0 (en) Method for reducing or alleviating inflammation in the digestive tract
EP2381920A4 (en) METHOD AND COMPOSITIONS FOR TREATING P.ACNES
EP2368028A4 (en) INTERNAL COMBUSTION ENGINE AND METHOD OF OPERATING SAME
EA201290158A1 (ru) Композиция и способ лечения диабета
WO2011081915A3 (en) Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
IL201254A0 (en) 5 - oxo - isoxazoles as inhibitors of lipases and phospholipases
WO2011155705A3 (ko) 장 내 콜레스테롤 흡수 억제를 통한 고지혈증 및 비만 억제용 조성물
WO2010117194A3 (ko) 지방산 계열 화합물을 유효성분으로 함유하는 위장 질환 예방 또는 치료용 조성물
WO2007100765A3 (en) Lysozyme-modified probiotic components and uses thereof
EA201391454A1 (ru) Композиция и способ лечения диабета
WO2011099000A3 (en) Pharmaceutical composition for treating the gastrointestinal tract

Legal Events

Date Code Title Description
FA Abandonment or withdrawal